This was the stock's second consecutive day of losses.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cybin (CYBN – Research Report) and Corbus ...

Corbus earlier announced the presentation of data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 (SYS6002) at the 2025 American Society of Clinical Oncology ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced that data from its US and UK first-in-human dose escalation ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...

Corbus Pharmaceuticals Inc. has placed its chips on “bets where somebody else is ahead of us,” CEO Yuval Cohen said. “The idea is to have a de-risked asset” that proves better in the clinic. At the ...